An Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody H2Mab-19 Exerts Antitumor Activity in Mouse Colon Cancer Xenografts

Yukinari Kato, Tomokazu Ohishi, Junko Takei, Takuro Nakamura, Masato Sano, Teizo Asano, Yusuke Sayama, Hideki Hosono, Manabu Kawada, Mika K. Kaneko

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Trastuzumab is a humanized antibody against human epidermal growth factor receptor 2 (HER2) that offers significant survival benefits to patients with HER2-overexpressing breast or gastric cancer. HER2 is also known to be overexpressed in colon cancers. In this study, a novel anti-HER2 monoclonal antibody (mAb), H2Mab-19 (IgG2b, κ) was characterized for its anticancer activity in colon cancers. H2Mab-19 showed both antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activities against Caco-2, a colon cancer cell line. Furthermore, H2Mab-19 significantly reduced tumor development in a Caco-2 xenograft model. These results suggest that treatment with H2Mab-19 may be a useful therapy for patients with HER2-expressing colon cancers.

Original languageEnglish
Pages (from-to)123-128
Number of pages6
JournalMonoclonal antibodies in immunodiagnosis and immunotherapy
Volume39
Issue number4
DOIs
Publication statusPublished - 2020 Aug 1

Keywords

  • HER2
  • antitumor activity
  • monoclonal antibody

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'An Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody H2Mab-19 Exerts Antitumor Activity in Mouse Colon Cancer Xenografts'. Together they form a unique fingerprint.

Cite this